Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30148484 | 0.99 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5864717 | 0.89 | SLC16A1 (0.83) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3827013 | 0.86 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3826398 | 0.86 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3826394 | 0.86 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL7677693 | 0.84 | SLC16A1 (0.76) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5864631 | 0.84 | SLC16A1 (0.76) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL5864752 | 0.84 | SLC16A1 (0.76) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL4847425 | 0.83 | SLC16A1 (0.75) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL8144478 | 0.82 | SLC16A1 (0.75) | SLC16A1CYP2C9CYP3A4SLC16A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125766-A1 | TREATMENT OR PREVENTION OF ISCHAEMIA REPERFUSION INJURY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20240252457-A1 | Treatment or Prevention of Ischaemia Reperfusion Injury | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| EP-4355315-A1 | TREATMENT OR PREVENTION OF ISCHAEMIA REPERFUSION INJURY | Cambridge Enterprise Limited (GB) | 2024-04-24 | — | — | EP | disclosed |
| US-20240109925-A1 | Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea | AIX-MARSEILLE UNIVERSITE (FR) | 2024-04-04 | — | — | US | disclosed |
| EP-4284352-A1 | ENHANCED ANTI-PROLIFERATIVE AND ANTITUMOR IMMUNE EFFECTS OF MITOCHONDRIA-TARGETED HYDROXYUREA | The Medical College of Wisconsin, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022263792-A1 | TREATMENT OR PREVENTION OF ISCHAEMIA REPERFUSION INJURY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022164901-A1 | ENHANCED ANTI-PROLIFERATIVE AND ANTITUMOR IMMUNE EFFECTS OF MITOCHONDRIA-TARGETED HYDROXYUREA | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252457-A1 | Treatment or Prevention of Ischaemia Reperfusion Injury | TNNI3, MPO, TXN | SLC16A1 1893/4885CYP2C9 3561/4885CYP3A4 4349/4885 |
| US-20240109925-A1 | Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea | MAVS, TUFM, SHMT2 | SLC16A1 668/4885CYP2C9 3411/4885CYP3A4 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.